Dental Caries and Other Aspects of Oral Health That Impact Patients With Hemophilia
Researchers sought to determine patterns of oral health in patients with hemophilia.
Hemophilia
Trials Included in Many Coagulation Factor Package Inserts Have Significant Biases
Researchers sought to determine whether biases were present in clinical trials included in the package inserts of coagulation factors used for the treatment of hemophilia.
Project GYM: Physical Fitness Improves Wellbeing in Young Men With Hemophilia
Researchers investigated the safety and feasibility of Project GYM, a personal trainer-led physical fitness program for young men with hemophilia.
New Study Evaluating BPA Use With Emicizumab Among Patients With Hemophilia A
Researchers are seeking to evaluate outcomes after initiation of emicizumab and concomitant BPAs in patients with hemophilia A and FVIII inhibitors.
Emicizumab Safe, Effective in Patients With Hemophilia A With FVIII Inhibitors
Researchers sought to determine whether emicizumab would be safe and effective in pediatric patients with hemophilia A with FVIII inhibitors.
Extension Study Shows Safety, Efficacy of rVIII-SingleChain for Previously Treated Hemophilia A
Researchers sought to determine whether rVIII-SingleChain therapy would be safe and effective as a long-term prophylaxis option for previously treated patients with hemophilia A.
PRO Tool, GOAL-Hēm, Now More Patient-Centric for Patients With Hemophilia
Researchers sought to revise the GOAL-Hēm patient-reported outcomes tool to be more patient-centric for patients with hemophilia.
Efanesoctocog Alfa Appears Effective in Severe Hemophilia A
Researchers sought to determine whether efanesoctocog alfa may yield high sustained FVIII activity and improve bleed protection in patients with severe hemophilia A.
Valoctocogene Roxaparvovec Evaluated in Severe Hemophilia A
In open-label study, substantial increase seen in factor VIII activity at weeks 49 to 52 of follow-up.
Gene Therapy Gets Fast Track Status for Hemophilia A
In preclinical studies, ASC618 has been shown to have at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered constructs.
- Loading...
Loading...
Next post in Bleeding Disorders
Loading... 
Loading...